RxDoctor Payments Data

Varinder Singh, MD

Interventional Cardiology · New York, NYNPI 1144214735

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.9%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Heartflow, Inc. at 33.5% of the total. Reporting peaked in 2019 at $12,288 and has fallen 93.2% since, to $838 in 2025.

$34,677in general payments, 2019–2025

Across 210 payments — averaging $165.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$12K
  • Medtronic$10K
  • CSL Behring$3K
  • Contego Medical, Inc$2K
  • Boston Scientific$2K
  • Cardiovascular Systems Inc.$2K
  • plus $4K from 12 others
$290,384in research payments, 2019–2025

Across 120 payments — averaging $2419.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$221K
  • Abbott$69K

What the payments were for

  • Consulting fees$8,81325%
  • Speaking & faculty fees$8,75025%
  • Travel & lodging$2,5997%
  • Food & beverage$14,51642%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,677 in reported general payments places this provider in the 75th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$139,782
Medicare patients
290
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$110,752
Repatha SureclickEvolocumab19$10,306
Metoprolol Succinate127$2,000
Ranolazine ErRanolazine13$1,195
Atorvastatin Calcium120$1,123
Rosuvastatin Calcium69$1,115
Ezetimibe17$588
ClopidogrelClopidogrel Bisulfate75$557
Losartan Potassium61$554
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$399
Carvedilol42$386
Amlodipine Besylate45$351
Omeprazole16$307
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide16$261
Isosorbide Mononitrate ErIsosorbide Mononitrate22$257

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →